第1回高大連携講座.ppt
|
|
|
- しほこ やまがた
- 7 years ago
- Views:
Transcription
1
2
3
4
5
6
7
8
9
10
11 medicine drug mederi medicina dry pharmaceutical pharmakon druggistpharmacistchemist chemist chemistry chemistry alchemy al chemy alchemy alchemist chemist
12 chemist
13
14
15
16
17
18
19
20
21
2
C o r n e l i u s The Science of E m o t i o n I z a r d The Psychology of Emotions Rusalova et al. Schwartz et al E M G 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 The science of emotion The psychology
13
Pharmaceutical Segment 12 13 14 Pharmaceutical Segment 15 16 Pharmaceutical Segment 17 GERMANY CHINA JAPAN U.S.A. KOREA SINGAPORE 18 Pharmaceutical Segment 19 20 Pharmaceutical Segment 21 22 Pharmaceutical
ちょっと覗こう.PDF
--- --- 40 1992.3 10 69 9 11 or 11 Dry farming 571 567 11 10 500 10 174 1972 50 1 100 2 10 1970 1994 1997 211 9 8 B.C.361 338 5 7 1000 500 500 3 1963 1250 2500 100 1986 1200 1998 1978 2001
204 / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January 2016 047
9 π 046 Vol.69-1 January 2016 204 / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January 2016 047 β γ α / α / 048 Vol.69-1 January 2016 π π π / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January 2016 049 β 050 Vol.69-1
★索引.indb
S 703 S 704 S 705 S 706 S 707 S 708 S 709 S 710 S 711 S 712 S 713 S 714 S 715 S 716 S 717 S 718 20 4 15 Japanese Journal of Medical Ultrasonics 35 101 0063 2 23 1 6 F The Japan Society of Ultrasonics in
- 26-23 13 23 25 27 26 18 2002 863 2.4 2.7
1138,500 15 72 117,230 530 112 14 752 1758,029 283 2001 23 185 187 35 2002 13 6,459 1,430-25 - - 26-23 13 23 25 27 26 18 2002 863 2.4 2.7 970 325,900,000 800,000 57,906 7.2% 200 52,900,000 0 0 6,378 80
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
CALL 1 e-learning CALL International Conference on Development of Dry Lands ( ) (HAC) HAC HAC HAC 1 17 5 1-109- 16 260
1 No.236 HP TAXUS
Drug Information News 1 No.236 HP http://www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/236.pdf TAXUS 186 12 1 1 3050 L 30L 7L 1 (1 ) ( ) 510mm 2 1 2 ph 10 2030 瘙 瘙 瘙 瘙 瘙 瘙 瘙 瘙
１１１博士最終報告
1 2 3 4 5 6 7 8 9 % () Residential School on Medicinal Chemistry Drew Nottingham Gordon Research Conference (Medicinal Chemistry) New Hampshire 10 11 12 13 14 27 15 16 17 18 - 19 20 21 22 ! 5!!!!! 21 2
産衛誌57-4たより.indb
A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al
2009年度 東京薬科大学 薬学部 授業計画
2009 2 234 Tokyo University of Pharmacy and Life Sciences since 880 Tokyo University of Pharmacy and Life Sciences Department of Clinical Pharmacy Men's Division Department of Clinical Applied Pharmacy
234 50cm
234 50cm () 1 10 2 3 4 1 5 6 2 2 1 7 ( ー ) っ ー っ 8 1 2 10 10 2m 4m 6m 15m 457-2472 585-1154 9 10 2 60 2 100 RC SRC 30 80 500 1 500 500 ) 10 B b A 2 A B 2m 457-2473 585-1154 11 20m a 2m 3 3 1m 75cm 120cm
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
iii iv v vi 21 A B A B C C 1 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 19 22 30 39 43 48 54 60 65 74 77 84 87 89 95 101 12 20 23 31 40 44 49 55 61 66 75 78 85 88 90 96 102 13 21 24 32 41 45 50 56 62 67 76 79
No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h htmL)
Drug Information News No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h0925-1.htmL) 2 No.192 HP DI [ ] 1. -1a - 50 100 300 2. 7501500 3000750 1500 3000 60009000 12000240006000 9000 12000 24000
04菊池氏.indd
KIKUCHI Sakae 1 1 1899 32 2000 1966 1.58 1990 1.57 2000.15 2 32 13 2 3 4 18 39.6 25 216,974 106,594 110,380 12 22 5 4.72 12 6 25 33 60 90 25 35 23 24 3 25 7 25 35 45 2 2002.9 4 1925 2003 1997 8 1975 25
CONTENTS
2003 TAISHO Environmental and Social Report CONTENTS 3 4 5 6 ) TAISHO PHARMACEUTICAL CO.LTD. ENVIRONMENT REPORT 7 8 TAISHO PHARMACEUTICAL CO.LTD. ENVIRONMENT REPORT 9 10 TAISHO PHARMACEUTICAL CO.LTD. ENVIRONMENT
4% P % 11.1%1, % %1, %1, % 3.5%1, % %1, % Santen Ph
Financial Section 11 5 54 56 58 59 6 63 http://www.santen.co.jp/ja/ir/document/securities.jsp Santen Pharmaceutical Co., Ltd. Annual Report 215 49 4% 215 3 214 3 P.8 2 98.4% 11.1%1,592 62 12.6% 25 69 1.6%1,618
表紙ＰＤＦ作成用／ＰＤＦ表紙作成用
2010 Vol.52 No.1 Jpn J School Health Jpn J School Health Aichi University of Education Jpn J School Health Yogo Jpn J School Health Jpn J School Health Educational and Social Survey Research Center,
技術の系統化調査報告「医薬品創製技術の系統化調査」
Systematized Survey on the History of Drug Discovery with Technical Development 2 Kohei Umezu Kohei Umezu 1 83 84 2 2.1 85 86 87 88 89 90 91 92 93 2.2 94 95 96 97 98 99 100 101 102 2.3 103 104 105 106
生物資源学2017／表紙
BIORESOURCES GUIDEBOOK 2016.06 CONTENTS Department of Sustainable Resource Sciences Department of Environmental Science and Technology Department of Life Science and Chemistry Department of Marine Bioresources
(核)41-1(05)報告33-46
33 Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 28th Survey in 2002) 6 * Subcommittee of Safety Issue for the Radiopharmaceuticals Medical and Pharmaceutical Committee Japan Radioisotope
48V () 70 50 60 4
4 4 4 4 5 5 5 5 6 6 6 6 7 7 7 7 7 ()7 7 8 8 ()8 9 9 9 10 11 11 11 ()12-12 12 13 13 13 13 13 15 16 16 16 16 16 17 17 17 18 48V () 70 50 60 4 -5mV/ BP Solar Block Sonnenschein Dry Fit Absolyte battery
untitled
2011/1/22 1 vs. 2 1 2011/1/22 3 4 2 2011/1/22 5 6 3 2011/1/22 7 8 4 2011/1/22 9 H 2 N NH 2 N N S S NH 2 N O 2 S NH2 N N H S CH 3 H N N CN HN CH3 10 5 2011/1/22 11 12 6 2011/1/22 13 14 7 2011/1/22 15 16
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
第５８巻３号／投稿規定・目次・表２・奥付・背
β Feature articles 1Basic knowledge for clinicians and industrial doctors Feature articles 2Several topics in the field of medical science and treatment β Staphylococcus aureus Reviews Case reports VDT
02
Q A Ax Pb Ni Cd Hg Al Q A Q A Q A 1 2 3 2 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 8 0 0 1 2 3 4 1 0 1 2 Q A ng/ml 4500 D H E A 4000 3500 3000 2500 2000 DHEA-S - S 1500 1000 500 0 10 15 20 25 30 35 40 45
1.医薬品開発forWeb.ppt
1 4/15 4/22 CC/TBDD(CADD) 5/6-1 1 5/6-2 1 4/15 BO:17-2-1-1 BO:17-2-1-1 Drug Discovery based on Genome (Information) Combinatorial Chemistry Random screening Lead Optimization target validation Target Validation
:
13111191111111 1111011711111 119191711 1111 1 10191019191 181918111 19181191111911111! 1 18118191???1919 1191181???1919 1719181918111???19 171813 191181???171913 11918111918171 1 11???17 11719191 1918101911
2.2 (1967) (1997,2003) 2.2 ( ) 11
( ) 2.1 10 2.2 (1967) (1997,2003) 2.2 ( ) 11 12 ( ) 90150 (684) (887) (1099) (1361) (1605) (1707) (1854) 21(1946) 8 2.3 (1854) 13 (1997) (1854.12.23) (M8.4) (24 ) (M8.4) 70,000 3000 ( ) 7 2 3 3 (,1997)
履 歴 書
,,,,,, Carboplatin and Monthly Paclitaxel Carboplatin and Weekly Paclitaxel 8(1), 25-34 (2006) Masayoshi KOINUMA, Takahisa YAMANASHI, Miwako KAMEI, Makoto SHIRAGAMI, The realities and Medical Expense of
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
History I COE
2008 108-8641 5-9-1 TEL 03-5791-6334FAX 03-5791-6335 e-mailgakufu@lisci.kitasato-u.ac.jp 228-8555 1-15-1 TEL 042-778-9760FAX 042-778-9761 e-mailnyushi@kitasato-u.ac.jp URL http://www.kitasato-u.ac.jp/lisci/index.html
Microsoft Word - 第58回日本脂質生化学会プログラムv1.doc
1 2 3 4 i-bac 1 1 2 2 3 2 3 2,4 1 2 3 i-bac 1 2 1 2 1 1,3 1 2 Wake Forest School of Medicine 1,2 1 1 Lawrence L. Rudel 2 1 1 2 1 1 1 1 2 2 1 1 2 3 4 1 2 3 2 2 2 2 4 1 2 1 2 1 1 2 1 1 1 1 2 3 1 1 1 1 3
日本目録規則1987年版改訂2版第2章図書改定案
2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3
低酸素症06.4.29.doc
mmhg Time of Useful Consciousness;TUC Effective Performance Time;EPT 1. 2. 3. 4. 36000ft/m 15 8,000feet 43,000feet HYPOXIA; The higher you fly the less air in the sky. Medical Facts for Pilots; AM-400-91/1,
橡NO005-PDF用.ec5
(Biotechnology, Cell Biology, Genetics, Immunology, Medicine, Neuroscience, Structural Biology) (Cancer, Genetics, Immunology, Molecular Cell Biology, Neuroscience) InfoPort TEL: 043-290-2262 FAX:
プラズマ核融合学会誌８月号【８２－１０】／解説＿Ｃｈａｎｇ
Physics and Chemistry of Atmospheric Plasmas CHANG Jen-Shih author s e-mail: changj@mcmaster.ca a b ab cv cv s x x y y x y μ μ μ m n xymn n n abcde f μ μ μ abcandde ab cde aicpbccpccavityd MPT Ar Brawn&Kunc
研修コーナー
l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,
Ｎｏ．１９
Views and Actions C Points of View boxwhisker plot EU ICH http wwwinfopmdagojp n n n n n n No n n n n n n pi pii pi pii pi pii n n n PKPD No HTBD HTBD CD LHRH RS HTBD EGFR AT DMARD HTBD HTBD TNFα α HMGCoA
% 28.0% % 28.5% % 27.0% % 20.1% % ,831
60,127 61,002 60,342 51,369 52,016 51,470 62,030 62,666 53,167 53,807 57,477 56,526 56,991 66,822 65,979 66,568 64,349 60,313 55,168 69,061 66,850 58,686 IMS HEALTH, World Review 2002 11 21.8 29.5% 28.0%
2014CSR.pdf
Performance Through Chemistry Corporate Social Responsibility Report CSR REPORT 2014 Responsible Care OUR COMMITMENT TO SUSTAINABILITY Contents 1 2 Responsible Care OUR COMMITMENT TO SUSTAINABILITY Top
2 4 診断推論講座 各論 腹痛 1 腹痛の主な原因 表 1 症例 70 2 numeric rating scale NRS mmHg X 2 重篤な血管性疾患 表
2 4 診断推論講座 各論 腹痛 1 腹痛の主な原因 表 1 症例 70 2 numeric rating scale NRS 4 10 50 160 90mmHg691836.3 X 2 重篤な血管性疾患 表 2 72 73 表 1 腹痛をきたす疾患の緊急度と治療担当診療科による分類 1 2 3 4 5 表 2 3 血管性疾患と炎症性疾患の症状 腹膜刺激症状 表 1 表 3 74 75 表 3 腹膜刺激症状を修飾する因子
MI( MI() 100% 100% 75% 75% 33% 75% 60% 40% 25% 60% 1 2 3 4 5 6 7 8 9 () 12 () () () !! 1. 2. 3. 1. 2. () () () 3-5% ex. ex. 11 ex. () ex. ex. : ex. : (insula) () () ( 2009 ) () ( ) YES! ()
GRAPHIC SCROLLS
GRAPHIC SCROLLS IVANA ARIESTA RYDER Table of Contents GRAPHIC SCROLLS... 2 A... 2 B... 3 C... 4 D... 5 E... 6 F... 7 G... 8 H... 9 I... 11 J... 12 K... 13 L... 14 M... 15 N... 16 O... 17 P... 18 Q... 19
化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]
![化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]](/thumbs/39/20150687.jpg "化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]")
(1) 1,2- DMP CAS 131-11-3 C 10 H 10 O 4 194.2 2 1) 5.5 2,3) 283.7 2,3) 1.192 (20 ) 4) 133 Pa (1 mmhg) (20 ) 5) 1ppm=7.94 mg/m 3 at 25, n- / 1.56 ( ) 6) 4) ( )3.2 (30 ph 7)11.6 (30 ph 9)25 (18 ph 9) 5)
1 2
1 2 Faculty of Science Department of Mathematics Department of Physics Faculty of Science 3 4 Faculty of Science Department of Chemistry Department of Biology Faculty of Science 5 6 Faculty of Science
bac2017_00_15
2017 Faculty of Bioscience and Applied Chemistry Department of Frontier Bioscience Department of Chemical Science and Technology Department of Clinical Plant Science TEL:03-3264-9300 http://www.hosei.ac.jp/
がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性
2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF
200823 877122 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment 200821 19518 19977 IF20082 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug
untitled
NO.50 2009 10 10 0570-058-669 http://www.i-nouryoku.com/index.html 35 45 1 29 () 40 1 NO.50 2009 10 ha1.5ha 1.5haha1.5ha 1.5haha 10ha ha [] 150 2 NO.50 2009 10 [] a [] 1.5ha 3 NO.50 2009 10 4 NO.50 2009
名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
. 1 EBM Evidence-Based Medicine JCAHO 2
1 1 . 1 EBM Evidence-Based Medicine JCAHO 2 . 2 3 . 4 . 5 . When Where Who What Why How 6 . 7 3 DPC . 20 30 8 20 30 . (1) 9 3 BP mm mm . (2) 10 . http://epath.medis.or.jp/ 11 . 12 . 13 . 14 15 . PDCA Plan
202
201 Presenteeism 202 203 204 Table 1. Name Elements of Work Productivity Targeted Populations Measurement items of Presenteeism (Number of Items) Reliability Validity α α 205 α ä 206 Table 2. Factors of
3 4 6 7 8 9 10 12 14 2 3
3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15
ゼリア新薬工業株式会社
C O N T E N T S TOP INTERVIEW Q A Q A Q A 10.9 22.9 66.2 ZERIA Pharmaceutical Co.,Ltd. 1 TOP INTERVIEW Q A 2 ZERIA Pharmaceutical Co.,Ltd. ZERIA Pharmaceutical Co.,Ltd. 3 Q A Q A Q A Q A R&D III II I II
20 57
56 20 57 58 59 12 60 ph 61 62 CCA 63 64 ( 1) 700 7.5 86% 54 17 71 2) 700 6.8 86% 50 15 65 3) 600 700 5.7 84% 36 14 50 550 650 4.2 80% 21 6 27 40 500 3.6 78% 16 7 23 3.6 78% 16 7 23 400 700 4.0 78% 18 7
. 0.18 0.16 0.16 0.14 0.12 0.1 0.08 0.06 0.067 0.0563 0.047 0.04 0.02 0 0.026 0.02 0.004 US US US Saudi Ar Jpn Fin EU 0.04%40.0023% n180030571000 10000n1/10 Partinen M, Hublin C: Epidemiology of Sleep
No21Vol1.indd
( ): - PSA Shojiro Kano Head, Working Group of PSA Testing Standardization Committee (PSA) PSA PSA JCCLS PSA A PSA B PSA PSA Wang PSA FDA Hybritech Tandem-R PSA PSA PSA PSA - (ACT) - (AMG) ACT (PSA-ACT)
NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml
NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008
プライマリ・ケア国際分類第2版教育セッションプログラム
1 5 (ICD-10) (WONCA) (ICPC) Problem Oriented Medical Record(POMR) SOAP S O A P ICPC-2 SOAP Evidence Based Medicine ICPC-2 2 WHO ICD-10 CD-ROM ICD-10 2 5 3 A03 2 30 42160 A 42 161216 204 ICPC-2 A Excel
X線分析の進歩36 別刷
X X X-Ray Fluorescence Analysis on Environmental Standard Reference Materials with a Dry Battery X-Ray Generator Hideshi ISHII, Hiroya MIYAUCHI, Tadashi HIOKI and Jun KAWAI Copyright The Discussion Group
24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD
Immunocompromised Children 24 RS24 24 RS 24 RSRespiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 1 RS 28 2935 12 6 RS BPD 246 1 1 CHD 24 24 24 2 RS [1] [1.1] RS 24 RS T DiGeorge Wiskott- Aldrich
目 次 受 賞 者 紹 介 スーザン ソロモン 博 士... 1 記 念 講 演 オゾン 層 破 壊 と 気 候 変 動 : 極 から 極 へ 単 独 旅 行... 3 受 賞 者 紹 介 グロ ハルレム ブルントラント 博 士... 117 記 念 講 演 持 続 可 能 な 開 発 に 向 け
平 成 16 年 度 ( 第 13 回 )ブループラネット 賞 受 賞 者 記 念 講 演 会 THE ASAHI GLASS FOUNDATION 目 次 受 賞 者 紹 介 スーザン ソロモン 博 士... 1 記 念 講 演 オゾン 層 破 壊 と 気 候 変 動 : 極 から 極 へ 単 独 旅 行... 3 受 賞 者 紹 介 グロ ハルレム ブルントラント 博 士... 117 記 念
Cmax AUCo-+on,l, fns/ml 76.468+ t'/.710 x x n=3 l1) Labroo,R.B.etal. : Drug Metab.Dispos. 1997; 25(9): 1072- r 080 l2) Schneider,E.et al. : Naunln Schmiedebergs Arch.Pharmacol. B0T0X'ror injection -0.09
説明書82：妊娠と抗てんかん薬★★.PPT
Preg-82 2002.8 Ⅰ. Nakane Y et al.: Multi-institutional study on the teratogenecity and fetal toxitity of antiepileptic drugs: A report of a collabolative study group in Japan. Epilepsia, 21; 663-680,1980.
Balaenoptera bonaerensis Balaenoptera bonaerensis Japanese Journal of Zoo and Wildlife Medicine 10(1) J. Cetacean. Res. Manage. 6(3) Systematic Biology 54(1) Mirounga leonina Balaenoptera
Novel chemical mediators in the resolution of inflammation Charles N. Serhan Key words E-mail : marita@nih.go.jp Charles N. Serhan Brigham & Women's Hospital/Harvard Medical School 1) Serhan, C. N.,
Special IssueOncology Nutrition Reviews Proceeding DNA β Nutrition and physical activity and the prevention of cancer Yutaka Taketani Department of Clinical Nutrition, Institute of Health Biosciences,
β β β β β β
β β β β β β β β β β β β β β β β β θ β α γ et al et al et al β β et al β et al in vivo et al γ et al et al et al et al et al et al Ectopic fat deposition, type 2 diabetes mellitus and cardiovascular diseases
JAPICCONTENTS 450 JAPIC CONTENTS No.15732003.9.22 5 3 50 7843 6271 Progress in Medicine Vol.23 No.62003 p1617-1621 2003 5 1959-1971 1973-1991 1999-2000 SSRI 2000 SNRI SSRISelective